ArticleBone marrow transplantation2002
Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases.
Article in Bone marrow transplantation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.Bone marrow transplantation · 2012Guideline
- Psoriasis in the transplant population.Archives of dermatological research · 2023Review
- Systemic juvenile idiopathic arthritis: The Great Ormond Street Hospital experience (2005-2021).Frontiers in pediatrics · 2023Article
- Case Report: Lessons Learned From Subsequent Autologous and Allogeneic Hematopoietic Stem Cell Transplantations in a Pediatric Patient With Relapsing Polychondritis.Frontiers in immunology · 2022Article
- Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.Blood advances · 2020Article
- Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives.International journal of molecular sciences · 2020Review
- Curability and transferability of atopy with allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2020Article
- T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica.Annals of clinical and translational neurology · 2019Article
- Small molecule inhibitor of TGF-β signaling enables robust osteogenesis of autologous GMSCs to successfully repair minipig severe maxillofacial bone defects.Stem cell research & therapy · 2019Article
- Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.Blood advances · 2018Article
- Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies-New Therapeutic Possibilities?International journal of molecular sciences · 2017Review
- Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.Nature reviews. Neurology · 2017Review
- [Allogeneic stem cell transplantation : An option for autoimmune diseases?]Zeitschrift fur Rheumatologie · 2016Review
- Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?Vox sanguinis · 2016Review
- Organ-on-a-chip: development and clinical prospects toward toxicity assessment with an emphasis on bone marrow.Drug safety · 2015Review
- Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome.Bone marrow transplantation · 2014Article
- Hematopoietic stem cell transplantation for systemic lupus erythematosus.Clinical & developmental immunology · 2012Review
- Article
- Successful allogeneic bone marrow transplantation for chronic myelomonocytic leukemia complicated by refractory aortitis.Bone marrow transplantation · 2010Article
- Allogeneic stem cell transplantation for rheumatic autoimmune diseases.F1000 medicine reports · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine the role of allogeneic, autologous and syngeneic hemopoietic stem cell transplantation (SCTx) as a treatment for severe autoimmune disease (AID) we performed a literature search employing Medline, Cancer Lit and abstract books for reports on transplants for blood disorders and a concomitant AID. All reviews, case reports and abstracts available between June 1977 and September 2001 were used and attempts made to update them by e-mail by the corresponding authors. Disease-free survival (DFS) after allogeneic SCTx for 23 patients with severe aplastic anemia was 78% at 16 years and survival in unmaintained remission of concomitant AID was 64% at 13 years. DFS after allogeneic SCTx for 24 patients with hematologic malignancies was 87% at 15 years and survival in unmaintained remission for concomitant AID was 70% at 11 years. DFS after autologous SCTx for 24 patients with hematologic malignancies was 48% at 6 years and survival in unmaintained remission for concomitant AID was 29% at 3 years. Among 30 patients given allogeneic SCTx 19 developed graft-versus-host disease (GVHD) and 11 did not. Upon clinically justified discontinuation of all immunosuppressive therapy, 3/11 patients without GVHD relapsed with their concomitant AID (freedom of AID-relapse 69% at 9 years), whereas none of 19 patients with GVHD did so (log rank: P = 0.0135). Freedom of AID-relapse was superior after allo SCTx compared to autologous SCTx (89% at 18 years vs 38% at 5 years; log rank: P = 0.0002). Our data suggest that a graft-versus-autoimmunity effect after allogeneic hemopoietic SCTx mediates elimination of autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.